e-learning
resources
Madrid 2019
Tuesday, 01.10.2019
Cellular responses and cell therapy in lung injury and repair
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Mesenchymal stem cell therapy in a model of chronic inflammatory lung disease
D. Doherty (Belfast, United Kingdom), L. Roets (Belfast, United Kingdom), R. Delaney (Belfast, United Kingdom), A. Krasnodembskaya (Belfast, United Kingdom), M. Mall (Berlin, Germany), C. Taggart (Belfast, United Kingdom), S. Weldon (Belfast, United Kingdom)
Source:
International Congress 2019 – Cellular responses and cell therapy in lung injury and repair
Session:
Cellular responses and cell therapy in lung injury and repair
Session type:
Poster Discussion
Number:
3855
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Doherty (Belfast, United Kingdom), L. Roets (Belfast, United Kingdom), R. Delaney (Belfast, United Kingdom), A. Krasnodembskaya (Belfast, United Kingdom), M. Mall (Berlin, Germany), C. Taggart (Belfast, United Kingdom), S. Weldon (Belfast, United Kingdom). Mesenchymal stem cell therapy in a model of chronic inflammatory lung disease. 3855
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Mesenchymal stem cell therapy reduces inflammation and damage in a model of chronic lung disease
Source: ERS Lung Science Conference 2017
Year: 2017
Mesenchymal stem cells and fibrotic lung diseases
Source: International Congress 2014 – Targeting lung fibrosis: from bench to bedside
Year: 2014
Mesenchymal stem cell therapy for severe emphysema
Source: ERS Lung Science Conference 2021
Year: 2021
Mesenchymal stem cell therapy for severe emphysema
Source: Virtual Congress 2021 – Repair and regeneration in chronic lung disease and lung cancer
Year: 2021
The therapeutic potential of the mesenchymal stem cell secretome in a mouse model of chronic inflammatory lung disease
Source: International Congress 2019 – Cellular responses and cell therapy in lung injury and repair
Year: 2019
Mesenchymal lineage formation in the lung during development and disease
Source: International Congress 2017 – Molecular pathways in lung development
Year: 2017
Immunotherapeutic strategy with mesenchymal stem cells modulating inflammation in an experimental model of COPD.
Source: Virtual Congress 2020 – New insight into the immunology of asthma and COPD
Year: 2020
Mesenchymal stem cell based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysacharride in mice
Source: Annual Congress 2008 - Border patrol: the alveolar barrier in lung injury
Year: 2008
Mesenchymal stromal (stem) cell therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury
Source: Eur Respir J, 59 (1) 2004216; 10.1183/13993003.04216-2020
Year: 2022
Characterizing lung resident mesenchymal stem cells in idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
Modelling human lung development and disease using pluripotent stem cells
Source: International Congress 2015 – Regenerative medicine of the lung: opportunities and threats
Year: 2015
Effects of autologous mesenchymal stromal cell treatment for severe emphysema on lung tissue: A clinical trial
Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease
Year: 2015
Mesenchymal stem cells in aging and IPF
Source: ERS Research Seminar 2017 – Integrating systems biology approach in idiopathic pulmonary fibrosis research
Year: 2016
Fludarabine in paediatric steroid-refractory inflammatory lung injury after stem cell transplantation
Source: Eur Respir J 2013; 41: 479-483
Year: 2013
Restrictive chronic lung function decline after haematopoietic stem cell transplantation
Source: Eur Respir J 2016; 47: 336-339
Year: 2016
Minimally cultured bone marrow mesenchymal stem cells ameliorate fibrotic lung injury
Source: Eur Respir J 2009; 34: 740
Year: 2009
Induced pluripotent stem cells for generating lung airway stem cells and modelling respiratory disease
Source: Eur Respir Monogr 2021; 91: 190-204
Year: 2021
Noninfectious infiltrative lung diseases after allogeneic hematopoïetic stem cell transplantation (HSCT)
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Stem cell therapy attenuates airway and lung parenchyma remodeling in a murine model of chronic allergic asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept